Pfanstiehl offers parenteral grade maltose for pharmaceutical formulations

Published: 26-Jan-2015

Used to stabilise protein therapeutics and intravenous IG infusions


Pfanstiehl, a Chicago, US-headquartered manufacturer of excipients and bioprocessing solutions, has added a new high purity, low endotoxin, maltose to its portfolio.

The multifunctional disaccharide product is manufactured in the US under strict cGMP, ICH Q7 compliant conditions, the company says.

Christopher Wilcox, VP, Sales & Marketing at Pfanstiehl, said maltose is used to stabilise protein therapeutics, intravenous IG infusions and as a bioprocessing aid.

'We are pleased to be able to make such a high quality material available for our clients,' he said.

According to the company, maltose has demonstrated a unique ability to prevent aggregation in IVIG solutions and to act as a bulking agent in final formulations.

'It should be considered alongside other tried and true carbohydrates such as trehalose, sucrose, and sorbitol when developing platforms for stabilising mAbs, ADCs, and vaccines,' the company said.

You may also like